Adrenergic beta-2 Receptor Agonists

"Adrenergic beta-2 Receptor Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS.

Descriptor ID	D058666
MeSH Number(s)	D27.505.519.625.050.100.200.200 D27.505.696.577.050.100.200.200
Concept/Terms	Adrenergic beta-2 Receptor Agonists Adrenergic beta-2 Receptor Agonists Adrenergic beta 2 Receptor Agonists Adrenergic beta2-Agonists Adrenergic beta2 Agonists beta2-Agonists, Adrenergic Adrenergic beta-2 Agonists Adrenergic beta 2 Agonists Agonists, Adrenergic beta-2 beta-2 Agonists, Adrenergic Adrenergic beta-2 Receptor Agonist Adrenergic beta 2 Receptor Agonist

Below are MeSH descriptors whose meaning is more general than "Adrenergic beta-2 Receptor Agonists".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Neurotransmitter Agents [D27.505.519.625]
Adrenergic Agents [D27.505.519.625.050]
Adrenergic Agonists [D27.505.519.625.050.100]
Adrenergic beta-Agonists [D27.505.519.625.050.100.200]
Adrenergic beta-2 Receptor Agonists [D27.505.519.625.050.100.200.200]
Physiological Effects of Drugs [D27.505.696]
Neurotransmitter Agents [D27.505.696.577]
Adrenergic Agents [D27.505.696.577.050]
Adrenergic Agonists [D27.505.696.577.050.100]
Adrenergic beta-Agonists [D27.505.696.577.050.100.200]
Adrenergic beta-2 Receptor Agonists [D27.505.696.577.050.100.200.200]

Below are MeSH descriptors whose meaning is related to "Adrenergic beta-2 Receptor Agonists".

Below are MeSH descriptors whose meaning is more specific than "Adrenergic beta-2 Receptor Agonists".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Adrenergic beta-2 Receptor Agonists" by people in this website by year, and whether "Adrenergic beta-2 Receptor Agonists" was a major or minor topic of these publications.

Bar chart showing 34 publications over 13 distinct years, with a maximum of 8 publications in 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2009	1	0	1
2011	2	0	2
2013	1	0	1
2014	1	1	2
2015	0	2	2
2016	3	1	4
2017	0	2	2
2018	4	0	4
2019	3	0	3
2020	6	2	8
2021	1	2	3
2022	0	1	1
2023	0	1	1

Below are the most recent publications written about "Adrenergic beta-2 Receptor Agonists" by people in Profiles.

Chupp G, Murphy KR, Gandhi HN, Gilbert I, Bleecker ER. Asthma control in the United States: Relationships between short-acting ?2-agonist and systemic corticosteroid use. Ann Allergy Asthma Immunol. 2024 Sep; 133(3):302-309.

View in: PubMed
Rabe KF, Rennard S, Martinez FJ, Celli BR, Singh D, Papi A, Bafadhel M, Heble J, Radwan A, Soler X, Jacob Nara JA, Deniz Y, Rowe PJ. Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic Obstructive Pulmonary Disease: A Biologics Outlook. Am J Respir Crit Care Med. 2023 08 15; 208(4):395-405.

View in: PubMed
Han MK, Ye W, Wang D, White E, Arjomandi M, Barjaktarevic IZ, Brown SA, Buhr RG, Comellas AP, Cooper CB, Criner GJ, Dransfield MT, Drescher F, Folz RJ, Hansel NN, Kalhan R, Kaner RJ, Kanner RE, Krishnan JA, Lazarus SC, Maddipati V, Martinez FJ, Mathews A, Meldrum C, McEvoy C, Nyunoya T, Rogers L, Stringer WW, Wendt CH, Wise RA, Wisniewski SR, Sciurba FC, Woodruff PG. Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function. N Engl J Med. 2022 09 29; 387(13):1173-1184.

View in: PubMed
Martinez FJ, Darken P, Dorinsky P. Perplexing mortality data from triple therapy trials in COPD - Author's reply. Lancet Respir Med. 2021 10; 9(10):e96.

View in: PubMed
Singh D, Donohue JF, Boucot IH, Barnes NC, Compton C, Martinez FJ. Future concepts in bronchodilation for COPD: dual- versus monotherapy. Eur Respir Rev. 2021 Jun 30; 30(160).

View in: PubMed
Barnes NC, Jones P, Lipson DA, Singh D, Martinez FJ. Letter to editor - a response to: 'efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review'. Expert Opin Pharmacother. 2021 05; 22(7):939-941.

View in: PubMed
Han MK, Lipson DA, Singh D, Martinez FJ. Reply to: 'evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies'. Expert Rev Respir Med. 2021 04; 15(4):577-578.

View in: PubMed
Rabe KF, Martinez FJ, Dorinsky P. Triple Inhaled Therapy in COPD. Reply. N Engl J Med. 2020 10 01; 383(14):1394-1395.

View in: PubMed
Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St Rose E, Ballal S, McLaren J, Darken P, Aurivillius M, Reisner C, Dorinsky P. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N Engl J Med. 2020 07 02; 383(1):35-48.

View in: PubMed
Lipson DA, Crim C, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Lettis S, Manchester P, Martin N, Midwinter D, Morris A, Pascoe SJ, Singh D, Wise RA, Martinez FJ. Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2020 06 15; 201(12):1508-1516.

View in: PubMed

People

Explore

Similar Concepts

Top Journals